Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Story Tempered? Government May Put Future Brownfield Buyouts Under Scrutiny; No Qualms On Greenfield Investments

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Whether increased acquisitions of large Indian companies by multinational companies presents a threat to public health is being considered by a high-level inter-ministerial group that may approve provisions that distinguish between "greenfield" and "brownfield" investments made in India by external organizations or agencies

You may also be interested in...

After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon

Agila, as its name suggests, was agile in correcting deficiencies outlined in an FDA 483 last month and is back on track to supply global customers like Pfizer, GSK and Eli Lilly. But Mylan’s planned buyout of Agila, Strides Arcolab’s cash cow, has hit a snag and been put on hold by India’s finance ministry.

Bureaucratic Infighting Keeps India Pharma Deals Hanging; Mylan’s Agila Buyout Caught In Crossfire?

Fresh doubts have been raised on whether to allow foreign investments in Indian companies, pitting two powerful government ministries on opposing sides of the battle.

Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect

MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts